Literature DB >> 6952289

Inhibition of the late asthmatic response to house dust mite by non-steroidal anti-inflammatory drugs.

A J Fairfax.   

Abstract

Bronchial provocation with house dust mite allergen in subjects allergic asthma may be followed by an early and a delayed phase of bronchospasm. The latter can be prevented by DSCG or by corticosteroids. A representative subject was studied to determine the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on the late reaction. Indomethacin, benoxaprofen or acetylsalicylic acid given before allergen exposure inhibited the delayed bronchospasm. Sodium salicylate was ineffective, as were indomethacin or benoxaprofen when given after the early phase of bronchospasm. The mechanism of action of these compounds was thought to be by inhibition of arachidonic acid metabolism via the cyclo-oxygenase pathway and this appears to be a pre-requisite for the appearance of a late reaction following house dust mite inhalation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6952289     DOI: 10.1016/0262-1746(82)90046-4

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  5 in total

Review 1.  Lung inflammation, its significance for asthma therapy.

Authors:  J Morley; D Smith
Journal:  Agents Actions       Date:  1989-01

Review 2.  Prostaglandins and the lung.

Authors:  S P Hanley
Journal:  Lung       Date:  1986       Impact factor: 2.584

3.  Asthma and anti-inflammatory drugs. Mechanisms and clinical patterns.

Authors:  A Szczeklik; R J Gryglewski
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

Review 4.  Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.

Authors:  G E Senna; G Passalacqua; G Andri; A R Dama; M Albano; L Fregonese; L Andri
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

5.  Nimesulide does not interfere with airway responsiveness in allergic asthma.

Authors:  V Brusasco; E Crimi; I Scaricabarozzi
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.